-
Review
June 9, 2025
- Prospects of Mendelian randomization in hepatology: a comprehensive literature review with practice guidance
- Lanlan Chen, Qi Rao, Menghan Gao, et al.
- Clin Mol Hepatol. 2025;31(4):1115-1138.
-
Review
June 24, 2025
- Update in the treatment of cirrhotic patients with portal vein thrombosis
- Jialin Wu, Xinyi Deng, Junyang Luo, et al.
- Clin Mol Hepatol. 2025;31(4):1139-1166.
-
Review
August 4, 2025
- Prospects of late-stage development agents in the treatment of metabolic dysfunction-associated steatohepatitis
- Brian Lee, Ussama Ghumman, Lisa D. Pedicone, et al.
- Clin Mol Hepatol. 2025;31(4):1167-1196.
-
Review
July 28, 2025
- Global strategies and actions to eliminate hepatitis B virus infection
- Chih-Lin Lin, Jia-Horng Kao
- Clin Mol Hepatol. 2025;31(4):1197-1212.
-
Review
August 4, 2025
- Taiwan liver cancer association management consensus guidelines for intermediate-stage hepatocellular carcinoma
- I-Cheng Lee, Hung-Wei Wang, Wei Teng, et al.
- Clin Mol Hepatol. 2025;31(4):1213-1232.
-
Original Article
December 13, 2024
- Plasma lipidomics and fungal peptide-based community analysis identifies distinct signatures for early mortality in acute liver failure
- Neha Sharma, Sushmita Pandey, Gaurav Tripathi, et al.
- Clin Mol Hepatol. 2025;31(4):1233-1251.
-
Original Article
June 2, 2025
- Genome-wide interaction study with body mass index identifies CYP7A1 and GIPR as genetic modulators of metabolic dysfunction-associated steatotic liver disease
- Oveis Jamialahmadi, Endrina Mujica, Lowri Morris, et al.
- Clin Mol Hepatol. 2025;31(4):1252-1268.
-
Original Article
June 4, 2025
- Distinct inflammatory imprint in non-cirrhotic and cirrhotic patients before and after direct-acting antiviral therapy
- Moana Witte, Carlos Oltmanns, Jan Tauwaldt, et al.
- Clin Mol Hepatol. 2025;31(4):1269-1284.
-
Original Article
June 13, 2025
- Non-contrast magnetic resonance imaging for detection of late recurrent hepatocellular carcinoma after curative treatment: a prospective multicenter comparison to contrast-enhanced computed tomography
- Dong Wook Kim, Won Chang, So Yeon Kim, et al.
- Clin Mol Hepatol. 2025;31(4):1285-1297.
-
Original Article
June 24, 2025
- Factors associated with hepatitis B mother-to-child transmission in a national prevention program
- Moran Ki, Byung-Woo Kim, Dahye Baik, et al.
- Clin Mol Hepatol. 2025;31(4):1298-1315.
-
Original Article
July 4, 2025
- Human cytomegalovirus reactivation in cirrhosis patients with acute decompensation
- Changze Hong, Zuxiong Huang, Yingli He, et al.
- Clin Mol Hepatol. 2025;31(4):1316-1332.
-
Original Article
August 8, 2025
- Hepatocytic ankyrin repeat and SOCS box protein 3 deficiency alleviates metabolic dysfunction-associated steatotic liver disease by decreasing ubiquitin-mediated carnitine palmitoyl transferase 1A
- Yuli Lin, Wulei Hou, Mengxiao Ge, et al.
- Clin Mol Hepatol. 2025;31(4):1333-1354.
-
Original Article
September 1, 2025
- Predictive machine learning model in intensive care unit patients with acute-on-chronic liver failure and two or more organ failures
- Yee Hui Yeo, Mengyi Zhang, Martin S. McCoy, et al.
- Clin Mol Hepatol. 2025;31(4):1355-1371.
-
Original Article
September 1, 2025
- Association of bile acid composition with synthetic pathways and efficacy of bezafibrate in cholestatic liver disease
- Manami Iida, Atsuko Higashida, Shuichi Ohtomo, et al.
- Clin Mol Hepatol. 2025;31(4):1372-1383.
This archive contains links to the full-text of all issues of Clin Mol Hepatol.
Current issue
|
All issues
-
Clinical and
Molecular
HepatologyPrint ISSN: 2287-2728
Online ISSN: 2287-285X
-
-
Video abstract
-
- Decoding platelet function in liver cirrhosis: A shift from quantity to quality
- Interventions targeting the gut-liver axis: A potential treatment strategy for metabolic dysfunction-associated steatotic liver disease
- Modulation of lymphatic vessels in management of liver disease and complications
- Metabolic dysfunction-associated steatotic liver disease across women’s reproductive lifespan and issues
- Examining the therapeutic landscape of beta-blockers in portal hypertension
- Immunopathogenesis of liver fibrosis in steatotic liver disease
- Evaluating the therapeutic efficacy of NAD supplementation in management of metabolic dysfunction-associated steatotic liver disease: Key considerations
- Recent updates on pharmacologic therapy in non-alcoholic fatty liver disease
- The role of the hepatic autonomic nervous system
- HBeAg-positive grey-zone patients: Treatment beyond guideline recommendations?
- Systemic therapy in advanced hepatocellular carcinoma
- Epidemiology and updated management for autoimmune liver disease
- Microbiome and metabolomics in alcoholic liver disease
- Personalized medicine in nonalcoholic fatty liver disease
- Acute on chronic liver failure in cirrhosis
- Current status and outcome of liver transplantation in South Korea
- History and future of hepatitis B virus control in South Korea
- Hepatocellular carcinoma statistics in South Korea
Impact Factor16.9First decision
07 Days
Publication after acceptance
05 Days
*Last 12 months
- MOST VIEWED (Last 6 months)
Viewed By
19809Epidemiology of metabolic dysfunction-associated steatotic liver disease Viewed By
15643Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment Viewed By
11095Global incidence and prevalence of nonalcoholic fatty liver disease Viewed By
11078Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma Viewed By
9221MAFLD: How is it different from NAFLD?
- MOST CITED (2023-2025)
Cited By
434Global incidence and prevalence of nonalcoholic fatty liver disease Cited By
420Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma Cited By
278MAFLD: How is it different from NAFLD? Cited By
206Epidemiology of metabolic dysfunction-associated steatotic liver disease Cited By
148Non-alcoholic fatty liver disease: Definition and subtypes
|
|||||||
